OncoMatch/Triple-Negative Breast Cancer (TNBC)/BRCA1

Triple-Negative Breast Cancer (TNBC)BRCA1 Clinical Trials

Germline BRCA1 pathogenic variants are enriched in TNBC relative to other breast cancer subtypes, accounting for approximately 10–15% of TNBC cases, and confer sensitivity to PARP inhibition and platinum agents through homologous recombination deficiency. Olaparib and talazoparib are FDA-approved for germline BRCA1/2-positive HER2-negative metastatic breast cancer. Trials investigate PARP inhibitor combinations with immunotherapy, platinum chemotherapy, and antibody-drug conjugates including sacituzumab govitecan.